AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01546194 — intervention group
Intervention type: OTHER
Intervention: Phone call explaining the research project
Description: A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
Study NCT01185678 — intervention group
Intervention type: DRUG
Intervention: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
Description: One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
Study NCT02079623 — intervention group
Intervention type: PROCEDURE
Intervention: Electroporation/ Nano knife treatment
Study NCT02079623 — intervention group
Intervention type: DEVICE
Intervention: NanoKnife
Study NCT02611895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV DNA
Description: Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
Study NCT04433767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks.
Study NCT01682291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modifications
Description: Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
Study NCT01682291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplements
Description: combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
Study NCT01469689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Google Adwords
Description: The investigators will display Google Adwords advertising the investigators' website offering online help for depression
Study NCT01469689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local organisation websites
Description: The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
Study NCT05146791 — intervention group
Intervention type: PROCEDURE
Intervention: Inlay Bristow
Description: A modified Bristow procedure
Study NCT05146791 — intervention group
Intervention type: PROCEDURE
Intervention: Bristow
Description: Traditional Bristow procedure
Study NCT02057055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap 300000027003
Study NCT02057055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap 300000029240
Study NCT01389219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections.
Study NCT04258696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
Study NCT04258696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrapak Knitted retraction cord
Description: using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
Study NCT02977546 — intervention group
Intervention type: DEVICE
Intervention: Noninvasive pulse contour analysis
Description: For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
Study NCT02977546 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary artery catheterization
Description: As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
Study NCT04175834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrizine
Description: prophylaxis
Study NCT04175834 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: diphenhydramine
Description: prophylaxis
Study NCT06458361 — intervention group
Intervention type: PROCEDURE
Intervention: Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis
Description: Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
Study NCT01450358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic regimen
Description: The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
Study NCT00375089 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: Individuals with Prader-Willi syndrome. Monitoring every 6 months.
Study NCT00375089 — intervention group
Intervention type: OTHER
Intervention: Group 2
Description: Individuals with Early-onset Morbid Obesity.
Study NCT03841864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV placement using ultrasound guidance vs traditional method
Description: Ultrasound guided IV placement
Study NCT01028209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PBR06
Description: Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
Study NCT03087266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FM-SRP
Description: Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
Study NCT03087266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
Study NCT01056744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with stent implantation
Description: Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)
Study NCT00214136 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: prostate radiation to 70Gy; nodal radiation to 56Gy
Study NCT02435693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHARMACEUTICAL CARE programe
Description: The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
Study NCT02435693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without PHARMACEUTICAL CARE programe
Study NCT02655913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
Study NCT02655913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated Electro-Hyperthermia (mEHT)
Description: MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
Study NCT03617016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Participants will receive domperidone tablets orally.
Study NCT03617016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to domperidone tablets orally.
Study NCT04331600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Oral chloroquine phosphate for 14 days
Study NCT04331600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedical supervision for 42 days
Study NCT04331600 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Telemedical supervision for 42 days
Study NCT04287920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acomprosate
Description: Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
Study NCT02620319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SX-ELLA Stent DV Tracheal (DV Stent)
Description: The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
Study NCT01286688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study NCT01286688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study NCT03232905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as tablet
Study NCT03232905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study NCT00943384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chronOS Strip
Description: chronOS strip combined with bone marrow aspirate plus local bone
Study NCT04943055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
Description: The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
Study NCT04943055 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: YAG lacrimal duct laser combined with lacrimal duct catheter
Description: The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
Study NCT03050528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
Study NCT00586105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: 400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
Study NCT03934385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Rehearsal
Description: After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
Study NCT03934385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
Study NCT03934385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
Study NCT01069783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels
Study NCT01069783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in two different dosage levels for the duration of the study
Study NCT01069783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once daily for the duration of the trial
Study NCT02981394 — intervention group
Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate Concentrate Injection
Description: BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
Study NCT00931151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postprandial metabolic and functional measures
Description: After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
Study NCT02798861 — intervention group
Intervention type: DEVICE
Intervention: Fibroscan 402/530
Description: Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
Study NCT02239666 — intervention group
Intervention type: OTHER
Intervention: NIS
Description: This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
Study NCT04013347 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal Resection
Description: Low Anterior Resection and Abdominoperineal Resection
Study NCT03050528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise
Description: Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
Study NCT03050528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
Study NCT02604238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
Study NCT01642030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.